Telik, Inc. was set up in 1988 and was reverse merged into privately held MabVax in May 2014.[1] The major drug of the company was TELINTRA, an investigational agent that was in development for the treatment of myelodysplastic syndrome (MDS) and idiopathic chronic neutropenia.[2]

Controversies

In 2007, a class action was filed against Telik, Inc., alleging that they made false and misleading statements about the Company’s business and prospects during the Class Period.[3]

References

  1. ^ "Reverse merger".
  2. ^ "Business Summary".
  3. ^ "Lerach Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit Against Telik, Inc".
Allikas: http://en.wikipedia.org/wiki/Telik
No tags for this post.